Replies to post #437150 on Amarin Corp Plc (AMRN)

[JRoon71]

Chromosome, I agree. And I also still firmly believe that once Amarin can move ahead with the new formulation, this aspect becomes even more magnified, as it means half the API, so roughly half the cost (give or take a little bit):

1) their cost structure is competitive with genetics which now seems to be even more realistic. This would portend more future formulary wins.

At that point, I'm not sure how generics could even begin to compete with V2.0.

More importantly, I believe at that point, Amarin could begin an active sales & marketing campaign again (or more likely, sell the company).